Day 3 Program

Rapid Fire 5

Day 3: December 10, 2026

4:30 PM–5:30 PM CST

Stars at Night 1-2

Session Details

Moderator

Allison Kurian, Stanford University, Stanford, CA

Moderator

Kimberley T Lee, University of Pennsylvania, Philadelphia, PA

RF5-2

De-escalated Denosumab (Every 12 versus Every 4 Weeks) Maintains Efficacy for Prevention of Symptomatic Skeletal Events in Patients with Bone Metastases: Breast Cancer Stratum from the Randomized Phase-III Non-Inferiority REDUSE Trial (SAKK 96/12)

Andreas Müller, Kantonsspital Winterthur, Winterthur, Switzerland

RF5-3

Pink! Leben: a randomized controlled trial of an acceptance and commitment therapy-based digital intervention for psychological distress in breast cancer patients across treatment phases

Christian Schem, Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany

RF5-4

Quality of life for patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes within the OPTIMA trial

Janet Audrey Dunn, University of Warwick, Coventry, United Kingdom

RF5-5

Temperature-controlled hand-foot cooling prevents chemotherapy-induced polyneuropathy (cipn): updated real-world data collection in 600 patients

Athina Kostara, MVZ Medical Center Duesseldorf, Duesseldorf, Germany

RF5-6

The role of estrogen plus progestogen on breast cancer incidence: a systematic review and meta-analysis of randomized clinical trials

Margaret S Pichardo, University of Pennsylvania,, Philadelphia, PA

RF5-7

Social drivers, age-at-onset, and later stage at diagnosis in association with aggressive RNA-based breast cancer subtypes among Black women

Sarah C Van Alsten, University of North Carolina at Chapel Hill, Chapel Hill, NC